At a glance
ClinicalIndex Comparison Record- ✓Childhood ALL in first relapse OR first hematological relapse after extramedullary relapse OR failure to achieve complete remission with frontline therapy OR lymphoblastic leukemia in first relapse
- ✓Age ≤21 years
- ✕Life expectancy less than 8 weeks
- ✕Mature B cell ALL
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
In Brief
A Phase 2 clinical trial evaluating Etoposide, cytarabine, vincristine, dexamethasone, methotrexate, teniposide, PEG-asparaginase, and 5 other interventions for Acute Lymphoblastic Leukemia and Lymphoma, Lymphoblastic. Completed, enrolled 47 participants across 2 sites.
Detailed Summary
The main purpose of this study is to find out how well participants with relapsed or refractory ALL respond to treatment with an etoposide- and teniposide-based induction chemotherapy regimen and what the side effects are. Primary Objectives: * To estimate the response rate for patients with refractory or relapsed ALL. * To estimate the survival rate of patients with refractory or relapsed ALL treated with risk-directed therapy.
Study Details
Timeline
Interventions
See Detailed Description section for details of treatment interventions.
See Detailed Description section for details of treatment interventions.
See Detailed Description section for details of treatment interventions.
See Detailed Description section for details of treatment interventions.
See Detailed Description section for details of treatment interventions.
See Detailed Description section for details of treatment interventions.
See Detailed Description section for details of treatment interventions.